KMT2C c.12145G>T ;(p.E4049*)

Variant ID: 7-151851226-C-A

NM_170606.2(KMT2C):c.12145G>T;(p.E4049*)

This variant was identified in 1 publication

View GRCh38 version.




Publications:


Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

Investigational New Drugs
Schneeweiss, Andreas A; Park-Simon, Tjoung-Won TW; Albanell, Joan J; Lassen, Ulrik U; Cortés, Javier J; Dieras, Veronique V; May, Marcus M; Schindler, Christoph C; Marmé, Frederik F; Cejalvo, Juan Miguel JM; Martinez-Garcia, Maria M; Gonzalez, Iria I; Lopez-Martin, Jose J; Welt, Anja A; Levy, Christelle C; Joly, Florence F; Michielin, Francesca F; Jacob, Wolfgang W; Adessi, Céline C; Moisan, Annie A; Meneses-Lorente, Georgina G; Racek, Tomas T; James, Ian I; Ceppi, Maurizio M; Hasmann, Max M; Weisser, Martin M; Cervantes, Andrés A
Publication Date: 2018-10

Variant appearance in text: MLL3: E4049*
PubMed Link: 29349598
Variant Present in the following documents:
  • Main text
  • 10637_2018_562_MOESM2_ESM.xlsx, sheet 1
  • 10637_2018_Article_562.pdf
View BVdb publication page